





Site SparkSM Presentations

July 25, 2026

Sponsored By:



PARTNERING FOR SUCCESS



2026 Judges



Paul Christensen

Life Clinical Research





Lauren MacNaughton

Pfizer



Kathryn Speed

PPD, a part of Thermo Fisher Scientific



2026 Finalists



Ashleigh Clarke
Grampians Health, AUS

Te Whatu Ora
Health New Zealand
Te Toka Tumai Auckland



Silvia Iglesias
Cancer and Blood Research, Auckland
City Hospital, Health New Zealand



Yang Song
Cancer Institute NSW, AUS

Faculty Disclosure



In compliance with ACCME Guidelines, I hereby declare:

I do not have financial or other relationships with the manufacturer(s) of any commercial services(s) discussed in this educational activity.

Ashley Clarke, Grampians Health

Silvia Iglesias, Cancer and Blood Research, Auckland City Hospital

Yang Song, Cancer Institute NSW

Lauren Stockwell, SCRS



Criteria for Awarding Contact Hours



Applicants must be present during the “live” event, contact hours are not issued for recordings.

Applicants must attend the activity the whole time, missing no more than ten minutes of the activity.

Applicants must complete the post-meeting survey with a score of at least 70%.

Applicants must complete the post meeting survey evaluation questions.

Society for Clinical Research Sites, Inc. is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.



2026 Finalists



**Grampians
Health**



Ashleigh Clarke
Grampians Health, AUS

Te Whatu Ora

Health New Zealand

Te Toka Tumai Auckland



Silvia Iglesias

Cancer and Blood Research, Auckland
City Hospital, Health New Zealand



Cancer Institute NSW



Yang Song

Cancer Institute NSW, AUS




PARTNERING FOR SUCCESS





WHO WE ARE




Current trial disciplines n=~108 trials open

Anaesthetics	Cardiology	Endocrinology	Gastroenterology
Haematology	Infectious Diseases	Intensive Care	Medical Oncology
Mental Health	Neurology	Obstetrics & Gynaecology	Paediatrics
Palliative Care	Renal	Surgery	Allied Health



WHAT WE SOLVED



- Phase I participant travel time average 45min [4min – 2hr 46min]
- ONE WAY



INNOVATION OVERVIEW



- Equipment: –80C, +4C, centrifuge, vitals monitoring, phlebotomy,
- Generator + battery back-up
- Secure network + SKILLED staff

Key Takeaways

1

WHAT YOU LEARNED

- Our journey so far: 1st patient consented and randomized on the van in January (remote patient monitoring trial for Atrial Fibrillation)
- Approved for Phase II oncology supportive care
- We underestimated how much our community would love it!



2

HOW OTHERS CAN IMPLEMENT

- Equipment is portable – could go in any fleet car
- Uses existing “hospital-in-the-home” or community nursing procedures
- 5 hospitals → one health service → one ABN → single governance
- Cost shifting: patient travel/accommodation reimbursement vs van expenses

3

FINAL NOTES

- Never forget the why



“Having the mobile unit pull up outside our home will make things so much easier..... I won’t have to travel two and a half hours to Ballarat for every trial visit” (Barry, Phase I trial patient)



Cancer Institute NSW

PARTNERING FOR SUCCESS





WHO WE ARE



Cancer Institute NSW




WHAT WE SOLVED



Surplus clinical trial consumables becoming clinical waste



INNOVATION OVERVIEW



Transforming surplus consumables into research resources

Key Takeaways

1

WHAT YOU LEARNED



9,284

Consumables
Redistributed



120 kgCO₂e

Total estimated
CO₂e Emissions
Avoided



\$2,386

Total estimated costs
savings including
incineration cost



14

Number of
research and education
units supported

2

HOW OTHERS CAN IMPLEMENT



Start with your
clinical trials unit.



Use an existing platform
(e.g. REDCap) to catalogue
surplus consumables.



Engage stakeholders early
and communicate the benefits.

3

FINAL NOTES

Small changes to existing
processes can transform waste
into resources.



Without intervention, these unused
resources become clinical waste.

The Team

Credits and Acknowledgements



Yang Song

Cancer Institute NSW



Narae Kim

Cancer Institute NSW



Celine Daignault

Cancer Institute NSW



Raymond Tangunan

Blacktown Hospital –
Medical Oncology
Research Unit



Joshua Neish

St Vincent's Hospital
Sydney –
Haematology Clinical
Research Unit



Cancer Institute NSW,
Western Sydney
Local Health District



**ST VINCENT'S
HOSPITAL**
SYDNEY



We thank the CTAs from Blacktown Hospital – Tara Fay, Pashtana Noori and Frederick Afeaki



Te Whatu Ora

Health New Zealand

Te Toka Tumai Auckland



WHO WE ARE

Clinical trials On-Site & DCT



Discipline	Open	In follow up	In setup	Total
Early Phase	11	8	5	24
Haematology	15	19	9	43
Haemophilia	1			1
Low Risk	6		1	7
Medical Oncology	23	34	10	67
Radiation Oncology	4	6		10
Radiation Oncology	1	11		12
Grand Total	61	78	25	164

Recruitment over last 3yrs:

	2023	2024	2025
Recruited	191	140	192



WHAT WE SOLVED

What was the challenge?

A highly manual and complex QA process for Participant Information Sheets led to long turnaround times and limited scalability

What was needed?

A scalable solution to improve consistency and reduce workload while maintaining quality, equity, and trust.

What didn't exist?

No standardised, AI supported approach existed to safely and consistently support QA review within a governed clinical research environment



INNOVATION OVERVIEW

What did you build?

An AI supported QA solution using Microsoft Copilot, with task-specific agents to assist review of Participant Information Sheets

How can it be replicated?

By using existing enterprise AI tools with structured prompts, phased validation, and strong governance frameworks

Who is it for?

Clinical research sites, particularly QA teams and Clinical Research Coordinators managing document-intensive workflows.

What does it solve?

It improves consistency, reduces manual workload and turnaround times, and enhances overall document quality

Key Takeaways

1

WHAT YOU LEARNED

- AI reduced turnaround times from up to two days to near real-time feedback, significantly improving efficiency
- AI is most effective when used for well-defined tasks with structured prompts and strong human oversight, weaker in contextual/visual checks
- Recognise when to stop optimising AI and rely on manual checks
- Successful AI adoption depends not only on technology, but on governance, training, and human judgment to ensure quality and trust

2

HOW OTHERS CAN IMPLEMENT

- How to get started

Identify a high-volume, repetitive QA process, start with a small pilot, use approved AI tools, and define clear SOPs and boundaries for safe use

- How to replicate

Engage governance, privacy, cultural, and legal stakeholders early, follow a phased validation approach, and support adoption through staff training and clear accountability



3

FINAL NOTES

- Focus on well-defined tasks
- Start small
- Build safe
- Start now!









LOOKING AHEAD

Breakout Sessions III & IV

Beyond Awareness:
Building Cultural Competency

Plenary Session



Site Spark Recipient Announcement & Closing

PARTNERING FOR SUCCESS



Please Join Us Now For The

NETWORKING BREAK

Sponsored By:

ThermoFisher
SCIENTIFIC

